Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance

Paul Kirk, John Paul Carpenter, Mark A Tanner, Dudley J Pennell*

Abstract

Background: Heart failure remains a major cause of mortality in thalassaemia major. The possible role of cardiac fibrosis in thalassaemia major in the genesis of heart failure is not clear. It is also unclear whether cardiac fibrosis might arise as a result of heart failure.

Methods: We studied 45 patients with thalassaemia major who had a wide range of current cardiac iron loading and included patients with prior and current heart failure. Myocardial iron was measured using T2* cardiovascular magnetic resonance (CMR), and following this, late gadolinium enhancement (LGE) was used to determine the presence of macroscopic myocardial fibrosis.

Results: The median myocardial T2* in all patients was 22.6 ms (range 5.3-58.8 ms). Fibrosis was detected in only one patient, whose myocardial T2* was 20.1 ms and left ventricular ejection fraction 57%. No fibrosis was identified in 5 patients with a history of heart failure with full recovery, in 3 patients with current left ventricular dysfunction undergoing treatment, or in 18 patients with myocardial iron loading with cardiac T2* < 20 ms at the time of scan.

Conclusion: This study shows that macroscopic myocardial fibrosis is uncommon in thalassaemia major across a broad spectrum of myocardial iron loading. Importantly, there was no macroscopic fibrosis in patients with current or prior heart failure, or in patients with myocardial iron loading without heart failure. Therefore if myocardial fibrosis indeed contributes to myocardial dysfunction in thalassaemia, our data combined with the knowledge that the myocardial dysfunction of iron overload can be reversed, indicates that any such fibrosis would need to be both microscopic and reversible.

Introduction

Thalassaemia is the commonest single gene disorder worldwide, with approximately 94 million heterozygotes for beta thalassaemia and 60,000 homozygotes born each year [1]. Life-long blood transfusions are required for survival in thalassaemia major, but with each unit of blood carrying 200-250 mg of iron, the transfusions result in tissue iron loading and multiple organ complications. Myocardial siderosis is the major cause of mortality and is dominantly manifested as heart failure [2], which typically has a disguised onset that may deteriorate catastrophically as a result of a vicious cycle of increasing intracellular iron levels. This toxic cardiomyopathy can be reversible if chelation is commenced early [3], although it may take years to reduce cardiac storage iron levels to normal. Although heart failure is clearly related to intracardiac iron, it is less clear whether there is an additional contribution from myocardial fibrosis. Myocardial fibrosis could reduce both systolic function and ventricular compliance which could aggravate iron mediated cardiac dysfunction. Another possibility is that cardiac fibrosis might occur as a result of periods of cardiac failure, and therefore its occurrence might indicate previous cardiac damage with recovery. Historical papers have suggested that cardiac fibrosis is a major pathological component of heart failure and death in cardiac siderosis [4-6], but this data is up to 50 years old and may be misleading in the current era of iron chelation treatment. There is rather little contemporary data examining the histological incidence of fibrosis in cardiac iron overload [7-9], and its relation...
to ventricular function and iron levels in thalassaemia patients [10]. Cardiac fibrosis can be studied using late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR). This technique uses an injection of a gadolinium chelate which is an MR contrast agent that concentrates in areas of expanded extracellular space, such as myocardial fibrosis, from 10 minutes after injection. LGE has been widely used to examine the role of replacement macroscopic fibrosis in a range of cardiomyopathies [11-14], and the occurrence of LGE is associated with the development of cardiac events, such as heart failure and arrhythmias [15-17]. CMR has also been used widely to measure storage cardiac iron with the T2* technique [18], which is non-invasive, reproducible [19,20], calibrated to cardiac iron levels [21-23], and a valuable technique to assess the efficacy of cardiac iron chelators [3,24-26]. We therefore used LGE and cardiac T2* to investigate the incidence of fibrosis and its correlation with myocardial iron and myocardial function in thalassaemia major patients.

Methods

Patients
A total of 45 patients with beta-thalassaemia major were included in this study. Patients were referred for clinical evaluation according to local practice at external referring centers. There were 19 male and 26 female patients with a mean (±SD) age of 27.1 ± 9.6 years. This research had full ethical approval through Trent NHS Ethics Committee, and all patients gave written consent.

Cardiovascular Magnetic Resonance
Patients were scanned at 1.5T (Sonata, Siemens Medical Solutions, Erlangen, Germany) using previously reported techniques [18]. In brief, T2* CMR was performed using a cardiac gated, single breath-hold, 8-echo sequence (2.6 - 16.7 ms, with 2.02 ms increments) of a single mid-ventricular short axis slice. Long axis cines and a contiguous stack of short axis cines were also acquired to assess left ventricular dimensions and function [27]. For T2* acquisition a large region of interventricular septum in a mid-ventricular slice was used. Following T2* acquisition, intravenous gadolinium-DTPA (0.2 mmol/kg) was administered and LGE images were obtained in multiple planes after 10 minutes [28]. Multiple acquisitions using an inversion recovery-prepped gradient echo sequence were obtained with incrementally increased inversion times (TI) until optimal contrast between normal and abnormal myocardium was obtained with TI = 250 ms. Data analysis was performed using CMRtools and its plug-in Thalassaemia Tools (Cardiovascular Imaging Solutions, London UK). All scans were reported in consensus by two independent experienced CMR readers.

Statistics

T2* values do not conform to a Gaussian distribution and are therefore presented as medians (Q1, Q3) unless otherwise stated. Comparison of T2* readings were made using the Mann-Whitney U test and comparisons of left ventricular indices were performed using Student’s t test. All normal variables are presented as mean ± SD and ranges or n (%) as appropriate. Statistical significance was set at P < 0.05.

Results

Overall patient cohort details
The baseline characteristics of the whole study group are shown in table 1. There were 42 subjects with normal left ventricular (LV) ejection fraction (EF > 56%) and 3 patients with current LV impairment with LVEF < 56% who were receiving cardiac treatment for heart failure. Five patients (11%) had a previous history of heart failure and 4 patients (9%) had history of documented arrhythmias, all of whom currently has normal LV function and no heart failure. The median (Q1, Q3)

| Total number of patients | 45 |
|--------------------------|----|
| Age (years)              | 27.1 ± 9.6 |
| Sex                      |    |
| Male                     | 19 |
| Female                   | 26 |
| Race/ethnicity           |    |
| White                    | 19 |
| South Asian              | 13 |
| Arabic                   | 8  |
| African                  | 5  |
| Units of blood transfused (units/year) | 32.2 ± 17.3 |
| Past history cardiac disease |    |
| Heart Failure            | 5 (11%) |
| Time between heart failure and scan (years) | 3.7 ± 7.6 |
| Arhythmia                | 4 (9%) |
| Time between arrhythmia and scan (years) | 40 ± 6.7 |

| CMR measures:            |    |
| Cardiac T2* (ms) median (Q1, Q3) | 22.6 (13.4, 34.5) |
| Liver T2* (ms) median (Q1, Q3)   | 4.4 (2.3, 8.5)    |
| LV end diastolic volume (mL)     | 134 ± 41.4        |
| LV end systolic volume (mL)      | 46.4 ± 20.2       |
| LV ejection fraction (%)         | 65.8 ± 8.5        |

Chelation

| No Chelation | 1 (2%) |
| Deferroxamine only | 21 (47%) |
| Deferiprone only  | 3 (7%)  |
| Deferasirox only | 9 (20%)  |
| Deferoxamine & deferiprone | 11 (24%) |
of myocardial T2* in all patients was 22.6 ms (range 5.3-58.8 ms). Of these patients, 27 had no significant iron loading (T2* > 20 ms), 15 patients had mild/moderate iron loading (T2* 10-20 ms) and 3 patients had severe iron loading (T2* < 10). At the time of the CMR scan, 1 patient was receiving no chelation (post bone marrow transplant), 21 patients were receiving deferoxamine, 3 patients deferiprone, 11 patients deferoxamine combined with deferiprone and 9 patients deferasirox only.

No myocardial iron loading group (T2* > 20 ms)
In these 27 patients, the myocardial T2* was 32.0 ms (26.5, 39.3), liver T2* was 6.8 ms (4.4, 21.0) and the LV EF was 68.3 ± 8.3%. No patient had a prior history of heart failure. There was fibrosis in one patient, (T2* 20.1 ms, and LVEF 57%) and there was no past history of heart failure or arrhythmia. The fibrosis was a small, discrete area in the subendocardium of the mid-inferolateral wall of the LV, with normal myocardial thickness throughout and no associated regional wall motion abnormalities (figure 1).

Mild/moderate myocardial iron loading group (T2* 10-20 ms)
In these 15 patients, the myocardial T2* was 13.1 ms (11.1, 15.4), liver T2* was 2.9 ms (2.1, 4.3) and the LV EF was 64.1 ± 6.2%. No patient had cardiac fibrosis despite 2 patients (4%) having a previous episode of heart failure. When compared with the normal group (T2* > 20), there was no significant difference in LVEF (p = 0.34).

Severe myocardial iron loading group (T2* < 10)
In these 3 patients, the myocardial T2* was 7.7 ms, liver T2* 2.2 ms and LV ejection fraction was 54.7 ± 3.5%. All 3 patients (100%) had a previous history of heart failure, but no patient has cardiac fibrosis. When compared with the normal group (T2* > 20) the LVEF was significant reduced (p < 0.01).

Discussion
Macroscopic cardiac fibrosis is detectable using LGE CMR and occurs commonly in non-ischemic heart disease such as dilated cardiomyopathy (DCM) [11,15], and hypertrophic cardiomyopathy (HCM) [12,17]. In DCM and HCM, the fibrosis is a driver of the development of LV dysfunction, and is directly linked to adverse cardiac outcomes such as heart failure and arrhythmias [15,17]. Historical post-mortem studies showed replacement cardiac fibrosis to be a prominent feature in thalassemia major patients [4-6], and therefore it is possible that cardiac fibrosis is important in the development of heart failure in thalassemia major. However, these studies are now up to 50 years old, which pre-dates the era of iron chelation treatment, and were biased towards patients who had died. More recent histology studies are limited and mainly in the unrelated genetic condition of hereditary hemochromatosis [7-9]. Our study in the modern chelation era of living patients, shows a low incidence of macroscopic myocardial fibrosis of 2% (1 in 45 patients), and in this one patient the fibrosis was very limited affecting only 0.4% of total left ventricular mass. This is

Figure 1 Late gadolinium enhancement in the thalassaemia patient. The arrows show a small area of fibrosis in the mid inferolateral wall of the left ventricle.
considerably lower than the replacement fibrosis typically seen in DCM (15%) [15,11] and HCM (30%) [17], and is unlikely to have any clinical relevance as studies in myocardial infarction predict a decrement in ejection fraction of only 0.27% in association with fibrosis of 0.4% of left ventricular mass [29]. If the fibrosis was due to cardiac siderosis, myocardial iron loading should be present, but the cardiac T2* was normal at 20.1 ms; or the patient might have current or a past history of heart failure, but this was not present and the ejection fraction was normal at 57%. The 47 year old male patient had not been investigated by the referring hospital for alternative, more prevalent causes of fibrosis, such as coronary disease, but was hepatitis C antibody positive.

Another significant discrepancy related to the possibility of cardiac fibrosis causing ventricular dysfunction in thalassemia major is that the dysfunction can be reversed with successful iron chelation therapy with intravenous deferoxamine [3], or combination deferoxamine-deferiprone [30]. The left ventricular ejection fraction increases as cardiac T2* improves, however there is no obvious pathophysiological mechanism for reversible effects of replacement fibrosis on ejection fraction. When the association of improved ejection fraction and improved cardiac T2* is married with the knowledge that low cardiac T2* is a potent predictor of future cardiac events [31], it becomes difficult to ascribe a significant clinical role to another factor such as putative reversible fibrosis. The lack of replacement fibrosis in our patients who had a history of heart failure or current left ventricular impairment would add credence to this position. We posit therefore that the left ventricular impairment seen in cardiac siderosis is a direct result of myocardial iron deposition and any contribution from replacement fibrosis is limited.

There is one previous study using CMR LGE in thalassemia from Pepe et al [10], which found LGE in 28 of 115 patients (24%). There are a number of possible explanations for the discrepancy of this study with ours. The LGE techniques or the interpretation of the images or the population studied may have differed between the 2 studies. The age and mean cardiac T2* of Pepe’s patients was 27.2 years and 24.5 ms, compared with 27.1 years and a median of 22.6 ms in our study, which excludes these as possible causal differences. However there was a high level of hepatitis C antibodies in Pepe’s patients (71%) which may indicate an additional mechanism for LGE such as myocarditis, which might resolve the differences in LGE prevalence between the 2 studies. In our study, only 11/49 (22%) patients were hepatitis C antibody positive, which included our one patient with LGE. We also note that the quantification of mean LGE extent by Pepe et al was 3.9% which indicates that the patches of fibrosis in their study were very limited and unlikely to be clinically significant with regard to cardiac dysfunction.

Limitations

LGE shows in-vivo macroscopic fibrosis, but interstitial fibrosis is too fine to be detected. However new techniques with T1 mapping [32], or steady state gadolinium infusions [33], to detect microscopic (non-replacement) fibrosis may prove useful. We have no tissue analysis from our study examining molecular markers of cardiac fibrogenesis. mRNA studies in ex-vivo cardiac myocytes have shown iron level dependent reductions in expression of transforming growth factor-β1 (TGF-B1), biglycan, and collagen type I, which was accompanied by a reduction in TGF-B1 bioactivity, which does not obviously support iron-driven cardiac fibrogenesis [34]. However, other studies suggest that myocytes can suppress proliferation of fibroblasts by cumulative effects on late G1 events leading to DNA synthesis, and these effects are diminished with myocyte iron accumulation [35,36]. A contemporary histology study in thalassemia major examining myocardium directly for interstitial fibrosis would be useful to add further evidence to the debate.

Acknowledgements

This work was supported by the NIHR Cardiovascular Biomedical Research Unit of Royal Brompton Hospital and Imperial College, London. This work was also supported by a National Institutes of Health Grant Award 5 R01 DK066084-02.

Authors’ contributions

PK and DP designed the study, collected the data and analyzed the results. JPC and MAT designed the study, assisted in collecting the data. All authors have read and approved the final manuscript.

Competing interests

Dr Penell is a consultant to ApoPharma, Novartis and Siemens, and is a director and stockholder in Cardiovascular Imaging Solutions. The other authors declare that they have no competing interests.

Received: 4 January 2011 Accepted: 17 January 2011 Published: 17 January 2011

References

1. Weatherall DJ: Anaemia as a World Health Problem. Oxford Textbook of Medicine Oxford University Press; 1996, 3463-82.
2. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ: Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008, 10:42.
3. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Penell DJ: Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004, 127:348-55.
4. MacDonald RA, Mallory GK: Hemochromatosis and hemosiderosis: study of 211 autopsied cases. Arch Intern Med 1960, 105:686.
5. Engle MA, Elflandson M, Smith CH: Late cardiac complication of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964, 30:698-705.
6. Buja LM, Roberts WC: Iron in the heart: etiology and clinical significance. Am J Med 1971, 51:209-12.
7. Sanyal SK, Johnson W, Jayalakshminarayana B, Green AA. Fatal “iron heart” in an adolescent: biochemical and ultrastructural aspects of the heart. Pediatrics 1975, 55:336-41.
8. Olson LJ, Edwards WD, McCall JT, Illstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987, 10:1293-9.
9. Olson LJ, Edwards WD. Endomyocardial biopsy in hemochromatosis: clinical-pathologic correlates in six cases. J Am Coll Cardiol 1989, 13:116-20.
10. Pepe A, Postano V, Capra M, Maggio A, Pinto CL, Spasiano A, Forni G, Derchi G, Fabbri B, Rossi G, Crucicelli E, Midiri M, Lombardi M. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassemia major. Heart 2009, 95:1688-93.
11. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Mehta A, Pennell DJ. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003, 108:54-9.
12. Moon JC, McKenna WJ, McCall JT, Ilstrup DM, Gersh BJ. Gadoliniumenhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005, 45:1683-90.
13. O’Hanlon R, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006, 48:1977-85.
14. Macera AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiac amyloidosis. J Cardiovasc Magn Reson 2008, 10:54.
15. Assomull RG, Prasad SK, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gaddolinium enhanced cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003, 24:2151-5.
16. Smedema JP, Snee G, van Kroonenburgh MP, van Grinsven WR, Gorgels AP, Crjns HJ. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005, 45:1683-90.
17. O’Hanlon R, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006, 48:1977-85.
18. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003, 18:333-9.
19. Westwood MA, Firmin DN, Gildon M, Renzo G, Markissa K, Vasili B, Pennell DJ. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassemia. Int J Cardiovasc Imaging 2005, 21:531-8.
20. Kirk P, Heath R, Anderson LJ, Gaddoliniumenhanced cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003, 24:2151-5.
21. O’Hanlon R, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006, 48:1977-85.
22. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003, 18:333-9.
23. Carpenter JP, He T, Kirk P, et al. Calibration of myocardial iron concentration against T2-star cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2009, 11(suppl 1):P224 (abstr).
24. Pennell DJ, Benshakhsa K, Karanagori M, Ladi Y, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferiprone in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107:5378-44.
25. Tanner MA, Galanello R, Desi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007, 115:1876-84.
26. Pennell DJ, Porter JB, Cappellini MD, B-Beale D, Anand L, Hyndman Y, Eflaty MS, Suchshtchyan P, Li C, Ibrahim H, Viprakasit V, Kattanis A, Smith G, Hab C, Domokos G, Roubert B, Tauer A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010, 115:2364-71.
27. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006, 8:171-8.
28. Kim R, Shah S, Judd R. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 2003, 5:505-14.
29. Shinki JE, Surti K, Farvid A, Shimbang JS, Colletti PM. Quantitative evaluation of the amount of delayed myocardial enhancement as a predictor of systolic dysfunction. Open Cardiovasc Med J 2009, 3:35-8.
30. Tanner MA, Galanello R, Desi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008, 10:12.
31. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961-8.
32. Iser L, Plufer J, Phrommittikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008, 52:1574-80.
33. Flott AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010, 122:138-44.
34. Parkes JS, Ping Liu, Sima JB, Templeton DM. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J Mol Cell Cardiol 2000, 32:333-46.
35. Liu Y, Templeton DM. The effects of cardiac myocytes on interstitial fibroblasts in toxic iron overload. Cardiovasc Toxicol 2001, 1:299-308.
36. Liu Y, Templeton DM. Iron-loaded cardiac myocytes stimulate cardiac myofibroblast DNA synthesis. Mol Cell Biochem 2006, 281:77-85.